Shanghai Pharmaceuticals Holding Co., Ltd
SHPMY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | 0.02 | 0.04 | -0.40 |
| FCF Yield | 2.41% | 7.72% | -7.46% | 5.50% |
| EV / EBITDA | 38.99 | 17.82 | 18.19 | 35.39 |
| Quality | ||||
| ROIC | 0.64% | 2.35% | 1.19% | 0.68% |
| Gross Margin | 10.19% | 10.84% | 10.25% | 11.36% |
| Cash Conversion Ratio | 2.26 | – | -1.65 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -5.15% | 3.14% | 4.54% | 5.82% |
| Free Cash Flow Growth | -94.70% | 195.39% | -218.38% | 35.78% |
| Safety | ||||
| Net Debt / EBITDA | 14.12 | 4.61 | 4.98 | 7.46 |
| Interest Coverage | 3.74 | 13.86 | 4.83 | 6.16 |
| Efficiency | ||||
| Inventory Turnover | 1.57 | 1.54 | 1.68 | 1.49 |
| Cash Conversion Cycle | 95.87 | 85.65 | 84.10 | 85.24 |